Neratinib

Going through breast cancer treatment Targeted therapies
1

Hello everyone,

 

I work in the Policy and Campaigns Team at Breast Cancer Care.

 

We need your help. The National Institute for Health and Care Excellence (NICE) are assessing whether or not to recommend  neratinib  to be available on the NHS in England for treating  early hormone receptor-positive HER2 positive breast cancer after adjuvant trastuzumab.

 

We are gathering evidence to contribute to NICE’s patient carer groups’ submissions and we want to hear from you. We will use the experiences of women who are on the clinical trial for neratinib to help us inform our response on what access to this drug would mean to women with hormone-receptor positive, HER2 positive breast cancer.

 

Please help us by completing our short survey:surveymonkey.co.uk/r/ZQYQTM9

 

We are looking for responses by 20 January 2019.

 

If you have any questions about our work in this area, please email campaigns@breastcancercare.org.uk

 

Thanks for your help,

Erin

2

Hello everyone,

There’s still time to respond to our survey and share your views on neratinib: surveymonkey.co.uk/r/ZQYQTM9

Thanks,

Erin